FORT COLLINS, CO / ACCESSWIRE / October 6, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the audit of the Company’s financial statements for fiscal 2021 is complete and that the Company today filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Form 10-K”) with the Securities and Exchange Commission (the “SEC”). With the Form 10-K now on file, the Company is focused on the completion and filing of the Forms 10-Q for the quarterly periods ended March 31, June 30, and September 30, 2022.
At the Company’s hearing before the Nasdaq Hearings Panel (the “Panel”), the Company presented its plan to evidence full compliance with Nasdaq’s filing requirement and all other applicable requirements for continued listing on Nasdaq and request an extension of time to do so. The Company is taking definitive steps to evidence compliance with the Nasdaq listing criteria as soon as possible; however, there can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will satisfy the Nasdaq listing criteria within any extension period that may be provided to the Company by the Panel. The Company plans to update the market promptly following receipt of the Panel’s determination after the hearing.
